Singapore markets close in 7 hours 43 minutes

LLY Dec 2022 260.000 put

OPR - OPR Delayed Price. Currency in USD
Add to watchlist
2.12000.0000 (0.00%)
As of 11:27AM EDT. Market open.
Full screen
Previous close2.1200
Open3.3000
Bid1.3600
Ask4.4000
Strike260.00
Expiry date2022-12-16
Day's range1.9000 - 3.3000
Contract rangeN/A
Volume9
Open interest116
  • Zacks

    LLY & PRTA in Spotlight on BIIB-Eisai's AD Drug Data

    The success of Biogen (BIIB)-Eisai's AD candidate in a big phase III study makes investors optimistic about the prospects of other AD candidates as well.

  • Motley Fool

    Why Biogen, Lilly, and Prothena Stocks Are Skyrocketing Today

    Shares of Biogen (NASDAQ: BIIB) were skyrocketing 36% as of 11:10 a.m. ET on Wednesday. The huge gain came after the company and its partner Eisai (OTC: ESALY) announced positive results on Tuesday from their late-stage Clarity AD study evaluating lecanemab in treating Alzheimer's disease. The news also propelled two stocks of other drugmakers developing Alzheimer's disease drugs significantly higher.

  • Zacks

    Biogen's (BIIB) Lecanemab Meets Goal in Alzheimer's Study

    Biogen (BIIB) and Eisai's Clarity AD study showed that treatment with lecanemab in the early stages of Alzheimer's disease reduces the rate of clinical decline on the CDR-SB scale by 27% compared to placebo.